Live price temporarily unavailable.
Exagen (XGN) is a Health Care company. Latest news and coverage below.
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $32.4M | $40.4M | $42.0M | $48.3M | $45.6M | $52.5M | $55.6M | $66.6M |
| Growth (year over year) | — | +24.5% | +3.9% | +15.1% | −5.7% | +15.3% | +5.9% | +19.7% |
| Gross profit | $17.1M | $21.6M | $25.4M | $27.7M | $21.3M | $29.5M | $33.1M | $38.8M |
| Gross margin | 52.6% | 53.4% | 60.6% | 57.4% | 46.9% | 56.1% | 59.5% | 58.3% |
| Operating income | −$4.88M | −$9.30M | −$15.2M | −$24.1M | −$46.1M | −$22.8M | −$13.6M | −$14.1M |
| Operating margin | −15.0% | −23.0% | −36.2% | −49.8% | −101.1% | −43.5% | −24.5% | −21.1% |
| Net income | −$8.01M | −$12.0M | −$16.7M | −$26.9M | −$47.4M | −$23.7M | −$15.1M | −$20.0M |
| Net margin | −24.7% | −29.8% | −39.8% | −55.6% | −104.0% | −45.1% | −27.2% | −30.0% |
| EPS (diluted) | −$293.34 | −$8.46 | −$1.32 | −$1.68 | −$2.77 | −$1.34 | −$0.83 | −$0.93 |
| Balance sheet | ||||||||
| Cash and equivalents | $13.2M | $72.1M | $57.4M | $99.4M | $62.4M | $36.5M | $22.0M | $32.2M |
| Total assets | $28.9M | $88.3M | $78.4M | $123.4M | $86.2M | $56.9M | $44.7M | $58.0M |
| Total liabilities | $35.6M | $32.7M | $36.5M | $38.5M | $43.8M | $34.3M | $35.1M | $40.6M |
| Long-term debt | $24.6M | $25.9M | $26.7M | $27.5M | $28.8M | $19.2M | $19.8M | $22.3M |
| Shareholders' equity | −$112.0M | $55.7M | $41.8M | $84.9M | $42.5M | $22.7M | $9.54M | $17.4M |
| Cash flow | ||||||||
| Operating cash flow | −$9.30M | −$9.71M | −$14.1M | −$20.3M | −$32.1M | −$14.5M | −$13.3M | −$13.6M |
| Capital expenditure | $199.0K | $403.0K | $455.0K | $2.37M | $4.32M | $828.0K | $515.0K | $641.0K |
| Free cash flow | −$9.50M | −$10.1M | −$14.5M | −$22.6M | −$36.5M | −$15.3M | −$13.8M | −$14.3M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $12.5M | $13.7M | $15.5M | $17.2M | $17.2M | $16.6M | $17.3M | $19.9M |
| Growth (year over year) | −6.8% | −0.8% | +7.5% | +14.2% | +37.9% | +21.8% | +11.7% | +15.9% |
| Gross profit | $6.98M | $8.48M | $9.12M | $10.4M | $10.1M | $9.21M | $10.2M | $12.2M |
| Gross margin | 55.8% | 62.1% | 58.9% | 60.4% | 58.4% | 55.4% | 59.0% | 61.3% |
| Operating income | −$4.66M | −$3.38M | −$3.37M | −$2.63M | −$3.10M | −$4.97M | −$3.41M | −$1.72M |
| Operating margin | −37.3% | −24.8% | −21.7% | −15.3% | −18.0% | −29.9% | −19.7% | −8.6% |
| Net income | −$5.03M | −$3.76M | −$3.75M | −$4.44M | −$7.09M | −$4.67M | −$3.97M | −$3.20M |
| Net margin | −40.2% | −27.5% | −24.2% | −25.8% | −41.1% | −28.1% | −22.9% | −16.0% |
| EPS (diluted) | −$0.28 | −$0.20 | −$0.20 | −$0.21 | −$0.31 | −$0.21 | −$0.17 | −$0.13 |
| Balance sheet | ||||||||
| Cash and equivalents | $22.0M | $22.0M | $11.2M | $30.0M | $35.7M | $32.2M | $21.5M | $24.6M |
| Total assets | $43.6M | $44.7M | $40.3M | $58.8M | $62.8M | $58.0M | $52.0M | $51.9M |
| Total liabilities | $30.7M | $35.1M | $33.9M | $37.7M | $44.7M | $40.6M | $37.5M | $39.7M |
| Long-term debt | $19.8M | $19.8M | $18.4M | $22.3M | $22.3M | $22.3M | $22.3M | $22.3M |
| Shareholders' equity | $12.9M | $9.54M | $6.40M | $21.0M | $18.1M | $17.4M | $14.4M | $12.2M |
| Cash flow | ||||||||
| Operating cash flow | −$2.18M | $363.0K | −$10.7M | −$2.88M | $2.94M | −$3.01M | −$10.4M | $3.99M |
| Capital expenditure | $147.0K | $146.0K | $113.0K | $209.0K | $275.0K | $44.0K | $228.0K | $543.0K |
| Free cash flow | −$2.32M | $217.0K | −$10.8M | −$3.09M | $2.67M | −$3.06M | −$10.6M | $3.44M |
From Exagen's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Exagen in our feed yet.